(Q37650321)

21 August 2017

1 reference

title

Zonisamide in the treatment of epilepsy (English)

1 reference

21 August 2017

author

Andreas Schulze-Bonhage

series ordinal

1

object named as

Andreas Schulze-Bonhage

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

11

1 reference

21 August 2017

issue

1

1 reference

21 August 2017

page(s)

115-126

1 reference

Prevalence and clinical features of epilepsy in a biracial United States population

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Early identification of refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

The management of refractory idiopathic epilepsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Place of polytherapy in the early treatment of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Bone health in people with epilepsy: is it impaired and what are the risk factors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide as adjunctive therapy for refractory partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Clinical pharmacology and therapeutic drug monitoring of zonisamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide enhances slow sodium inactivation in Myxicola

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Biphasic effects of zonisamide on serotonergic system in rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Antiepileptic activity of zonisamide on hippocampal CA3 neurons does not depend on carbonic anhydrase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Efficacy of zonisamide: our experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Pharmacokinetics and drug interactions with zonisamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Antiepileptic drug treatment: outcomes and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Drug compliance of children and adolescents with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide: chemistry, mechanism of action, and pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Overview of Japanese experience-controlled and uncontrolled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide clinical trials: European experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Efficacy and safety of zonisamide: results of a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide as add-on treatment for focal epilepsies. An outcome analysis of 74 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide: physician and patient experiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Anticonvulsant treatment with zonisamide added to topiramate. A preliminary treatment analysis in 19 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide monotherapy in a multi-group clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Effects of zonisamide monotherapy in children with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Long-term efficacy and safety of zonisamide monotherapy in epilepsy patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Psychiatric comorbidity and hostility in patients with psychogenic nonepileptic seizures compared with somatoform disorders and healthy controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide-induced restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Effects of zonisamide on the electroencephalogram of a patient with juvenile myoclonic epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Clinical efficacy of zonisamide in childhood epilepsy after long-term treatment: a postmarketing, multi-institutional survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide in pediatric epilepsy: review of the Japanese experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome)--a nationwide questionnaire survey in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Early-infantile epileptic encephalopathy with suppression-bursts, Ohtahara syndrome; its overview referring to our 16 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide treatment for symptomatic infantile spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide in West syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Treatment of infantile spasms with zonisamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Successful zonisamide treatment for infants with hypsarrhythmia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide for absence seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Long-term observations of two siblings with Lafora disease treated with zonisamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Molecular analysis and anticonvulsant therapy in two patients with glucose transporter 1 deficiency syndrome: a successful use of zonisamide for controlling the seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide (CI-912) and cognition: results from preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide in epilepsy: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in patients with refractory partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide-induced behavior disorder in two children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Practical prescribing and long-term efficacy and safety of zonisamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Increased propensity for calcium phosphate kidney stones with topiramate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Safety of topiramate: adverse events and relationships to dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

A long-term follow-up of zonisamide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide and associated oligohidrosis and hyperthermia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide for the treatment of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Therapeutic role of zonisamide in neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Zonisamide prophylaxis in refractory pediatric headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

Practical Issues in the Management of Hypersensitivity Reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903468728

10.1517/14656560903468728

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference